Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

• Published in: Drug Design, Development and Therapy
• Main Authors: Hardin EA, Chin KM
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-11-01
• Subjects: Selexipag; pulmonary arterial hypertension; prostacyclin
• Online Access: https://www.dovepress.com/selexipag-in-the-treatment-of-pulmonary-arterial-hypertension-design-d-peer-reviewed-article-DDDT
• ISSN: 1177-8881

Elizabeth Ashley Hardin,1 Kelly M Chin2 1Department of Internal Medicine, Division of Cardiology, 2Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA Abstract: Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag. Keywords: selexipag, pulmonary arterial hypertension, prostacyclin